HIV-1 SEQUENCE HETEROGENEITY 3 7 SUBJECTS AND METHODS Case reports. Patient I is a 26-y-old homosexual male who was found to be HIV-1 seropositive 2 mo after donation of blood used for transfusion of the six pediatric patients when the HIV-1 serologic assay became available. He was asymptomatic for 3.4 y when he presented with oral hairy leukoplakia. He was started on azidothymidine therapy 5 y after diagnosis of HIV infection and has otherwise remained asymptomatic. CD4 counts of this patient have remained stable between 300 and 500/mm2.
Patient 11, a female, was the product of a 30-wk gestation whose neonatal course was complicated by moderate-to-severe hyaline membrane disease with pneumothoraces, hyperbilirubinemia, apnea, bradycardia, intraventricular hemorrhage with subsequent hydrocephalus, and anemia requi-sion. At 8 mo of age, she was failing to thrive and suffered from persistent oral and perineal candidiasis. She was first tested and found to be positive for HIV-1 antibodies at 12 mo of age. Over the next year, she was frequently hospitalized for complications of interstitial pneumonitis, chronic diarrhea, and Hemophilus influenzae otitis media. She was treated with i.v. gamma globulin at a dose of 400 mg/kg every month. She had severe developmental delay, cortical blindness, and atropy. She died at 20 mo of age from the complications of a viral pneumonia.
Patient I11 was a male, prematurely delivered at 29 wk of gestation as a result of an incompetent cervix. He developed respiratory distress after vaginal delivery. His neonatal course was complicated by mild hyaline membrane disease with right upper lobe collapse, bronchopulmonary dysplasia, right subependymal hemorrhage, intraventricular hemorrhage, apnea, bradycardia, and anemia that required blood transfusion. At 35 d of life, neutropenia and thrombocytopenia developed, which resolved spontaneously after 3 mo. Failure to thrive, lymphadenopathy, and hepatosplenomegaly were noted at 7 mo of age. He subsequently developed pneumococcal meningitis and was treated with i.v. Ig 400 mg/kg every month. He was first tested and found to be positive for HIV-1 antibodies at 12 mo of age. He had multiple hospital admissions for evaluation of possible sepsis, chronic diarrhea, and recurrent scabies. Gastroenteritis was associated with repeated culture of Aeromonas hydrophilia from his stools. The patient manifested developmental delay and regression as well as cerebral atrophy and frontal lobe and basal ganglia calcifications. His clinical course was marked by multiple infections. He was treated with azidothymidine but died at 31 m o of age.
Patient IV, a 940-g female, was the product of a 27-wk gestation. Pregnancy was complicated by chronic hypertension and preterm labor. The infant developed respiratory distress immediately after vaginal delivery. The neonatal course was complicated hy severe hyaline membrane disease progressing to bronchopulmonary dysplasia, grade I1 intraventricular hemorrhage, recurrent apnea, and retinopathy. She received multiple blood transfusions. After discharge at 95 d of age, she did not gain weight and was seen frequently in the emergency room for otitis and cough. On these occasions, extensive oral candidiasis was noted. Candida skin tests and lymphocyte proliferation responses t o Candida were negative. At 9 mo of age, she was admitted to the hospital in a marasmic state with a history of chronic diarrhea. Though HIV-1 antibodies were not examined, HIV-1 p24 antigen was found to be positive. Severe cerebral atrophy was diagnosed by computed tomography scan. The patient died at 9 mo of age of a cardiorespiratory arrest.
Patient V, a male, was the 730-g product of a 27-wk gestation complicated by severe preeclampsia. The patient was delivered by cesarean section. The patient's neonatal course was complicated by moderate hyaline membrane disease and bronchopulmonary dysplasia requiring intubation. He underwent a patent ductus arteriosis ligation and was evaluated on numerous occasions for sepsis. He exhibited bone demineralization and stage I1 retinopathy. He was discharged from the hospital at 4 mo of age but was readmitted for complications of recurrent viral infections, including respiratory distress and one prolonged tonicclonic seizure. Growth and speech milestones have been delayed, but development has otherwise been normal. There were no cerebral atrophy or intracranial calcifications detected by computed tomography scan. Since 8 mo of age, he has had only occasional episodes of otitis media and no other serious infections. He has been treated with intramuscular 100 mg/kg gamma globulin/mo, and has remained well for more than 7.5 y after HIV-1 infection.
Informed consent. Informed consent was obtained from all patients (or parents or guardians) who participated in this study. Human experimentation guidelines of the US Department of Health and Human Services and of Washington University School of Medicine Institutional Review Board were followed in the conduct of the clinical research.
MATERIALS AND METHODS
Virus isolation was performed by cocultivation of PBMC from the patient with an equivalent number of phytohemagglutininactivated PBMC from an uninfected donor (20). Cultures were grown for 12 wk in RPMI 1640 medium supplemented with 15% FCS, 5% IL-2, 2 mM glutamine, 100 units/mL penicillin, and 100 pg/mL streptomycin. An equal number of fresh phytohemagglutinin-activated PBMC from an uninfected donor were added weekly.
Uncultured PBMC and cultured cells were washed in PBS and suspended in 100 pL PBS, followed by the addition of 500 pL of lysis buffer (1% SDS, 1% 2-mercaptoethanol, 10 mM Tris-CI, pH 8.0, 150 mM NaC1, and 5 mM EDTA). Proteinase K was added to a concentration of 300 pg/mL, and the cell lysate was incubated at 37°C for 60 min. DNA was extracted with phenol and chloroform and precipitated with ethanol.
The first round of nested PCR was performed on 0.5 pg of DNA in 50 mM KCI; 10 mM Tris-C1, pH 8.3; 7 mM MgCll; 400 pM of each deoxyribonucleotide triphosphate; and 2.5 units of thermostable Taq DNA polyermase (Perkin-Elmer Cetus, Norwalk, CT). The inital round of PCR used envelope primers JA9Eco (nucleotides 7 137-7 156) (5) and JA 12Eco (7572-7533) (2 1). PCR was performed in a Perkin-Elmer Cetus thermocycler programmed for 24 repeated cycles of target DNA thermal denaturation at 95°C for 30 s, oligonucleotide primer annealing at 50°C for 30 s, and Taq DNA polymerase-catalyzed template extension at 75°C for 30 s plus an additional 21s cycle. One and a half mL of the first-round amplified DNA product were transferred to the second round of PCR, which was performed with envelope primers JA 1 OEco (nucleotides 7 19 1-72 10) and JAl lEco (nucleotides 7532-75 13) with the identical conditions used in the first round of PCR but with only 4 mM MgCI2. All primers were 31 mers with 20 bases of sequences capable of annealing with HIV-1 sequences (2 1) and 1 I bases containing an EcoRI site. The predicted error rate for PCR under these conditions is <0.05% (22).
The expected 341-bp fragment was digested with EcoRI and cloned into the EcoRI site on pUC 19 using standard techniques (23). Dideoxynucleotide sequencing (24) was performed using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, OH) according to the manufacturer's recommendations, and complete sequences were obtained from both strands of each plasmid. All sequence numbers except those noted above for PCR primers were in accordance with a previous study (I). Sequences were submitted to Genbank as accession no. L06256-L06273.
RESULTS
The current study involved the transfusion of a single unit of HIV-1-infected blood from an asymptomatic adult to six premature infants (Fig. 1) . The transfusion occurred in January, 1985, before the availability of HIV-1 serologic assays. The transfusion donor, patient I, developed HIV-1-related symptoms 3.4 y after the transfusion. Four of the six pediatric patients were found to be HIV-1 infected. No other risk factors for HIV-1 infection were identified among the children or their mothers. No information about HIV-1 status is available for the other two pediatric patients who died of complications of their premature deliveries and for whom no tissues were preserved for HIV-1 status.
Three of the four HIV-1-infected pediatric patients, patients 11, 111, and IV, developed symptomatic HIV-1 disease and died of complications of AIDS within the first 3 y of life. In contrast, the fourth HIV-1-infected child, patient V, has remained asymptomatic for more than 7 y since acquiring HIV-1 infection.
Viremia was noted in patients 11, 111, and IV at all determinations of p24 antigen (Fig. 2) . In contrast, p24 antigen was undetectable at all times in patient V. Though HIV-1 was cultured from the blood of patient V at 1.0, 5.4, and 5.7 y of age, six other cultures between 1.0 and 5.4 y of age were negative ( Fig. 1 and data not shown) . In contrast, all culture attempts from patients I1 and I11 yielded infectious virus as measured by reverse transcriptase or p24 antigen assays.
Declining CD4:CD8 ratios were noted for patients I1 and 111, and patient IV had a low CD4:CD8 value at the only determination (Fig. 2) . In contrast, CD4:CD8 ratios consistently ranged between 1.0 and 1.5 over the first 48 mo of life for patient V, then subsequently declined to 0.5. Ig levels, reflecting B cell activation (26), were elevated in both patients I1 and I11 initially, but were slightly below the normal range for patient V.
A previous study reported the nucleotide sequences for the entire env gene of cultured isolates from patients I, 11, and I11 (I). This included 13 clones from seven isolates derived from blood, lung, and brain tissues. No differences were noted in the region containing the V3 principal neutralizing loop, nucleotides 794-1083. In the current study, nucleotide sequences obtained from HIV-1 isolates of patient V, whose clinical course differed significantly from those of patients I1 and 111, were compared with the sequences obtained from HIV-1 isolates of patients I1 and 111. For this purpose, PCR was used to amplify distinct sequences from HIV-1 quasispecies present in a cultured isolate obtained from patient V at 5.4 y of age and from uncultured peripheral blood leukocytes obtained at 4.0 and 6.3 y of age. Additionally, sequences were determined for clones from uncultured peripheral blood leukocytes of the blood donor, patient I, obtained in July 1989 and September 199 1.
Six clones were sequenced from PCR products of uncultured leukocytes of patient V obtained in February 1989 (4.0 y of age; clones VU 11-VU 16), and these clones exhibited sequences identical to each other and to that of clone IC 1, derived from a cultured isolate in June 1986 (Fig. 3) . Seven clones were sequenced from PCR products of the uncultured leukocytes (VU I-VU 7) obtained in April 1991 (6.3 y of age), and five unique sequences were obtained. Amino acid substitutions, deletions, and insertions relative to each other and to corresponding se-Age (mos.) quences of a cultured isolate and earlier uncultured isolates derived from both patients are shown in Figure 3 .
Six clones were sequenced from PCR products of the cultured isolate (VC 2, VC 3, VC 5, VC 6, VC 7, and VC 8; Fig. 3 ). Four of these sequences were unique with respect to each other and with respect to other available HIV-1 sequences.
Five clones were sequenced from PCR products of uncultured leukocytes of patient I obtained in July 1989 (IU 8-IU 12), and these clones exhibited sequences identical to each other and to that of clone IC 1 (Fig. 3) . Seven clones were sequenced from PCR products of uncultured leukocytes of patient I obtained in September 1991 (IU 22, 23, 27, 28, 30, 31, 32, 33) , and the positions of amino acid alterations are indicated. Also included for comparison in Figure 3 are the sequences of representative isolates from North American or European patients, WMJ2 and HXB2, and a representative isolate from an African patient, ELI (3).
Analysis of the V3 region included both interperiod and intraperiod sequences for cultured and uncultured isolates over a 5-y period. The sequence divergence was greatest in the uncultured isolates from late time points. In the isolates derived from uncultured leukocytes obtained in 1989 from both patients I and V, identical predicted amino acid sequences were found in comparison to those of earlier cultured isolates of patients I, 11, and 111. However, in the uncultured 1991 samples, both patients displayed marked heterogeneity. Intraperiod divergences for isolates from late time points from patients I and V were 2.1-16.6 and 0-13.5%, respectively ( Table 1) . Comparisons of the same late time-point isolates to the early time-point isolates showed 14.5-19.8 and 6.3-1 6.6% differences, respectively. Analysis of late time-point isolates with respect to the earlier isolates revealed 30 amino acid substitutions over 96 positions for patient I and 25 substitutions for patient V. Of these mutations, 50% are shared with respect to amino acid positions. In spite of the similarities noted in these two patients, who have experienced a relatively benign infectious course thus far, both patients also demonstrate unique sequence alterations.
Higher levels of amino acid divergence (2 1.8-27.1 %) were noted in comparison to other representative North American or European isolates, WMJ2 and HXB2 (Table 1 ). In comparisons of sequences from isolates of patients I and V to the African isolate, ELI, a sequence divergence of 48% was noted for early time points and ranges of 41.0-47.9% and 43.0-44.8%, respectively, for the 199 1 uncultured isolates.
Analysis of the V3 loops in these isolates demonstrated that the isolates derived from 1989 samples differed from the North American consensus sequence (27) at three amino acid positions, which expands to a range of three to seven amino acid substitutions in the late time-point isolates in patient I and two to five amino acid substitutions in patient V.
Cysteine residues flanking the V3 immunodominant loop are conserved in all isolates. Furthermore, the V3 loop is 35 amino acids long in all isolates. In HXB2, it is 36 amino acids long, and in WMJ2 and ELI it is 34 amino acids long. Two potential N-glycosylation sites at residues 298 and 322 are conserved in all isolates. Six additional potential N-glycosylation sites are present between amino acid residues 235, and 331 are found in some isolates. HIV-I sequences from patient I demonstrated a conservation of the N-glycosylation site at position 306, but evolving sequences demonstrated a shift in position by two amino acids for the N-glycosylation site to position 304. Also of note is the termination codon at position 305 in clones VC 2 and VC 6. Differences in predicted amino acid sequences among isolates from patients V and I and those from representative North American and African isolates are also noted in Figure 3 . The V3 loop is predicted to be located between disulfide bonded cysteine residues 263 and 297. The frequency of residues near the tip of the loop has been determined in a previous study examining 245 sequences from diverse HIV-1 isolates (27) , and the frequency for which each amino acid is found at that particular position is indicated. Three residues in the V3 loop, proline a t position 278, tyrosine at position 283, and aspartic acid at position 287, have been implicated in regulation of cell tropism of HIV-I for monocytes or primary glial cultures (28, 29) . The tyrosine has also been shown to regulate cytotoxic T-cell responses to the HIV-1 envelope (17). A cleavage site for thrombin, tryptase, and an endogenous Chinese hamster ovary cell protease is found between arginine 280 and alanine 281 (12-14).
Amino acid sequence differences within the V3 loop are noted at eight different positions among the clones from patient V (April 1991) and 10 positions among clones from patient I (September 1991) compared with the clones from earlier time points and among clones from patients I1 and 111. Three of these changes are unusual compared with previously described V3 loop sequences: a serine for arginine 27 1, a proline for threonine 275, and a serine for arginine 280. Leucine 276 in IC 1, an unusual amino acid at this position, is replaced by isoleucine in eight of 19 clones from patient V. This amino acid residue is found in 82% of other V3 loop sequences. The substitution of arginine for aspartic acid 287 may affect HIV-I tropism for monocytes (Henkel T, Westervelt P, Carrillo A, Trowbridge DB, Ratner L, unpublished observations).
DISCUSSION
This study offers a unique opportunity to study related isolates with respect to temporal, clinical, and genetic progression of HIV-1 sequences.
Transmission of HIV-1 by blood transfusion accounts for 2.6% of HIV-1 infections and 1 1.1 % of pediatric HIV-I cases (30, 3 1) . In the cohort examined here, all four children who shared the same unit of HIV-I-contaminated blood and for whom tissues were available were found to be HIV-1 infected. The high rate of acquisition of HIV-1 by transfusion has been noted in previous studies (32, 33) .
The indolent clinical course of patient V is clearly distinct from the rapidly symptomatic and fatal HIV-1 disease manifested in patients I1 and 111. Although plasma virus cultures were not performed in this study, it is likely that the virus load was significantly lower in patient V than patients I1 and 111. Only three of I0 lymphoblastoid cultures from patient V were positive, whereas all virus cultures of samples from patients I1 and I11 yielded infectious virus. Furthermore, serum p24 antigen levels were undetectable in patient V but elevated in patients I1 and I11 at all determinations (Fig. 2) .
The laboratory evidence of gradual immunologic deterioration in patient V is contrasted with the rapid deterioration seen in patients I1 and I11 (Fig. 2) . This is manifested by quantitative studies of the CD4+ lymphocyte population as well as an examination of polyclonal B cell activation as measured by serum Ig levels. Both of these parameters have been reported to be important prognostic markers for progression of HIV-1 disease in children (26) .
The range of clinical sequelae of HIV-1 infection identified in this cohort reflects the wide range of disease manifestations seen in other infected pediatric populations. It is unlikely that quantitative or qualitative differences in the virus inoculum account for the marked differences in clinical sequelae, inasmuch as similar amounts of contaminated blood were used for transfusion of each of the neonates. Furthermore, the range of viral species in the donated blood was quite restricted (1). Therefore, the current study examined the range of viral quasispecies present in patient V (and the blood donor, patient I), focusing on the V3 immunodominant loop to assess a region known to interact with the host cell and possibly affect infectivity by changes in sequence during disease evolution.
HIV-1 sequences were cloned from both virus cultured in primary lymphocytes and uncultured leukocytes. Previous studies have suggested that CD4+ lymphocytes are the predominantly infected cell type in blood of infected patients (34) . Thus, the cellular source of viral sequences was likely similar in each case. However, it is notable that the level of sequence diversity obtained from cultured virus was more restricted than that obtained from uncultured cells (Table 1) However, either of these methods may yield defective clones of the virus. In this regard, it is noteworthy that a termination codon is present in two of the clones from the cultured isolates (Fig. 3) 
